Last reviewed · How we verify
NCT06728852: Vigor
Efficacy and Safety of Vorolanib Monotherapy As Third-line or Later Treatment for Advanced Non-small Cell Lung Cancer Patients: a Single-arm, Prospective, Open-label Phase II Clinical Study
Phase 2 trial testing Administration of Vorolanib in Advanced Non-small Cell Lung Cancer (NSCLC) in 32 participants. Currently enrolling.
1 December 2026
Quick facts
| Lead sponsor | Li-kun Chen |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 32 |
| Start date | 1 December 2024 |
| Primary completion | 1 December 2026 |
| Estimated completion | 1 December 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Administration of Vorolanib — full drug profile →
Conditions studied
- Advanced Non-small Cell Lung Cancer (NSCLC) — all drugs for Advanced Non-small Cell Lung Cancer (NSCLC) →
- Recurrent or Metastatic Lung Cancer — all drugs for Recurrent or Metastatic Lung Cancer →
- Third-line and Beyond Therapy — all drugs for Third-line and Beyond Therapy →
- Angiogenesis Inhibition in Oncology — all drugs for Angiogenesis Inhibition in Oncology →
Sponsor
Li-kun Chen — full company profile →
Who can join
Adults 18 to 70, any sex, with Advanced Non-small Cell Lung Cancer (NSCLC) or Recurrent or Metastatic Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study evaluates the efficacy and safety of Vorolanib as monotherapy for advanced non-small cell lung cancer (NSCLC) patients receiving third-line or higher treatments. It is a single-center, single-arm, prospective Phase II clinical trial. Thirty-two patients who have undergone at least two lines of systemic therapy and exhibited progression or recurrence will receive 300 mg of Vorolanib daily until disease progression, intolerable toxicity, withdrawal of consent, or death. The primary endpoint is the 6-month progression-free survival (PFS) rate. Secondary endpoints include PFS, objective response rate (ORR), disease control rate (DCR), overall survival (OS), and safety. This research aims to expand the clinical applications of Vorolanib in NSCLC, providing a basis for further investigation.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The Spatiotemporal Heterogeneity of Tumor-Associated Stromal Cells: Reprogramming Plasticity to Unlock Precision Cancer Immunotherapy.
Lv Y, Duan T, Song J, Liu S, et al · · 2026 · cited 1× · PMID 41625480 · DOI 10.34133/cancomm.0002
Verify or expand the search:
- PubMed search for NCT06728852
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Li-kun Chen trials
Trials by the same sponsor.
- NCT07197008 — Sacituzumab Tirumotecan (Sac-TMT) Plus Bevacizumab in 3rd Generation EGFR-TKI Treated Advanced EGFR-mutant Nonsquamous N · Phase 2 · not yet recruiting
- NCT06728865 — Evaluation of the Efficacy and Safety of Furmonertinib Combined with Bevacizumab As First-Line Treatment for EGFR-Positi · Phase 2 · recruiting
- NCT04978753 — the Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metas · Phase 2 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06728852 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Li-kun Chen
- Last refreshed: 11 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06728852.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing